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About this report
This report presents the key activities performed by the EMCDDA and Europol in 2013, 
with details on all the relevant activities in support of the implementation of Council 
Decision 2005/387/JHA on the information exchange, risk assessment and control 
of new psychoactive substances, including new psychoactive substances notified in 
2013, Joint Reports produced, risk assessments conducted and public health alerts 
and advisories issued.
Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk-




I 1. Background to this report
As part of the response to new psychoactive substances within the European Union (EU), 
the Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, 
risk-assessment and control of new psychoactive substances (hereafter ‘the Council 
Decision’) established a mechanism for the rapid exchange of information on substances 
that may pose public health and social threats, including the involvement of organised 
crime. This provides a legal basis for the institutions of the EU and the Member States to 
monitor all new narcotic and psychotropic substances that appear on the European drug 
scene. Where necessary, the Council Decision also provides for an assessment of the risks 
associated with these new substances, so that control measures deriving from Member 
States’ obligations to the United Nations drug control conventions (1) can also be applied 
to new psychoactive substances.
Under Article 4 of the Council Decision, the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) and Europol, in close collaboration with their respective expert 
networks, the Reitox National Focal Points and Europol National Units, are assigned a 
central role in detecting, notifying and monitoring new psychoactive substances. The 
information exchange element of the Council Decision has been implemented by the 
EMCDDA and Europol as the European Union Early Warning System on New Psychoactive 
Substances (hereafter ‘Early Warning System’). In addition, where necessary, and in 
cooperation with the European Medicines Agency (EMA), the EMCDDA and Europol may 
collect, analyse and present information on a new psychoactive substance in the form of a 
Joint Report (Article 5). This report provides evidence to the Council of the European Union 
and the European Commission on the need to request a risk assessment on a new 
psychoactive substance. Such a risk assessment examines the health and social risks 
posed by a new substance, including: the use of, manufacture of and traffic in a new 
psychoactive substance; the involvement of organised crime; and the possible 
consequences of control measures. In order to conduct the risk assessment, the EMCDDA 
convenes a special meeting under the auspices of its Scientific Committee, extended with 
additional experts as necessary (Article 6).
To ensure transparency in the implementation of the Council Decision, Article 10 
stipulates that: 
‘The EMCDDA and Europol shall report annually to the European Parliament, the Council 
and the Commission on the implementation of this Decision. The report will take into 
account all aspects required for an assessment of the efficacy and achievements of the 
system created by this Decision. The report shall, in particular, include experience relating 
to coordination between the system set out in this Decision and the Pharmacovigilance 
system.’
In compliance with Article 10, the EMCDDA and Europol herewith present the eighth such 
annual report, which covers the period 1 January to 31 December 2013. The report 
outlines the results of the implementation, describes key issues arising from accumulated 
experiences and serves as a monitoring tool. The reader is referred to the full text of the 
Council Decision, to facilitate the reading of this report (2).
(1)  The 1961 United Nations Single Convention on Narcotic Drugs and the 1971 United Nations Convention on 
Psychotropic Substances.
(2)  Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk-assessment and control of new 
psychoactive substances, OJ L 127, 20.5.2005, p. 32.
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This report is written as a standalone document in which annexes have been kept to a 
minimum. The annex provides a list of new psychoactive substances that were first notified 
in 2013. It includes the systematic chemical name, the reporting country and the date of 
notification for each substance. Further information on these substances is available from 
the EMCDDA and Europol.
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I 2. New psychoactive substances in 2013
Since 1997 the EMCDDA and Europol have played central roles in the response to new 
psychoactive substances. Together, the two agencies, supported by their networks and 
other partners, have operated the world’s only regional early warning system on new 
psychoactive substances, a system that has underpinned the ability to identify and 
respond to new psychoactive substances that pose social and public health harms within 
the EU.
During 2013 a total of 81 new psychoactive substances were reported for the first time 
within the EU (section 4.1). This compares to 74 in 2012 (3), 49 in 2011 and 41 in 2010.
It should come as little surprise to most people that the majority of new psychoactive 
substances are intended as ‘legal’ replacements of controlled drugs. The year 2013 
provided further evidence that entrepreneurs and, increasingly, organised crime groups 
are expanding on the types of substances they plan to offer as ‘legal’ alternatives. Of 
particular concern to the EMCDDA and Europol in this respect are the new synthetic 
opioids — such as AH-7921, MT-45, carfentanil and ocfentanil — reported in the past two 
years. 
Until about a decade ago, most new psychoactive substances that emerged were typically 
sold on the illicit drug market. They were sometimes sold as drugs in their own right or as a 
new type of ‘ecstasy’, but often they were sold surreptitiously as amphetamine and MDMA. 
Only a few were reported each year. Usually these were stimulant-type or hallucinogenic 
drugs produced in Europe or the United States either in small amounts in amateur 
laboratories or on a commercial scale in clandestine laboratories by organised crime 
groups. New substances also occasionally emerged from the diversion of medicines. 
Importantly, this continues to be the case, with some of these substances simply acting as 
temporary substitutes for established controlled drugs that are in short supply, such as 
MDMA; while others, such as 4-methylamphetamine, appear to be produced accidentally 
as a result of the use of uncontrolled precursors in the production of amphetamine.
Only a few years ago the issue of new psychoactive substances was regarded as having 
limited significance to drug policy. In the past few years, however, there have been 
phenomenal changes in this market. Today the question of how to respond to the 
challenges posed by the emergence of new drugs has become a major concern within the 
EU and at the international level.
The sale of new psychoactive substances through an open market took off in mid-2000s 
with the stimulants 1-benzylpiperazine (BZP, a piperazine derivative) and methylone, 
followed by mephedrone (cathinone derivatives). This marked the start of the modern ‘legal 
highs’ and the ‘research chemicals’ market. Many of the new substances that are destined 
for these markets are produced in bulk outside the EU (e.g. China and India) and imported 
into Member States, where they are processed, packaged and sold. Europol has received 
reports that such operations occur in a number of Member States. The marketing and 
distribution of these drugs has reached a new level of sophistication. This includes through 
the Internet (with next day delivery to consumers), bricks and mortar ‘head shops’ in towns 
and cities, and via street-level drug dealers.
(3)  The 2012 Annual Report listed 73 substances as notified through the Early Warning System in 2012; this figure 
should have been 74. The synthetic cannabinoid JWH-302 (1-pentyl-3-(3-methoxyphenylacetyl)indole) was 
identified by Germany in August 2012 but was not included in the 2012 Annual Report.
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Globalisation and the new opportunities provided by developments in information 
technology have transformed many aspects of the new psychoactive substance market. A 
key player here is the Internet. Commerce and communication are no longer constrained 
by physical or geographical boundaries. This has also meant that the back catalogue of 
chemical substances developed by the pharmaceutical and medical research industries, 
whose psychoactive properties may make them attractive to consumers, is easily 
accessible to those wishing to identify such substances. Manufacturers in the chemical 
industries in China and India are able to synthesise the substances in bulk amounts. New 
trends also diffuse more rapidly, and a market for psychoactive substances has been 
created that exists, to a large extent, outside the established regulatory frameworks. 
As noted, 81 new psychoactive substances were reported for the first time within the EU 
during 2013. Twenty-nine of these substances were synthetic cannabinoids (4). This brings 
the total number of synthetic cannabinoids reported since December 2008 to 104, making 
them the largest group of substances monitored by the Early Warning System; the large 
number clearly illustrating the continuing attempts by manufacturers to produce new 
substances in order to circumvent drug control measures. Also reported in 2013 were: 
14 phenethylamines, 7 synthetic cathinones, 7 arylalkylamines, 5 opioids, 
2 benzodiazepines, 1 tryptamine, 1 aminoindane, 1 arylcyclohexylamine, 1 piperidines/
pyrrolinde, 1 piperazine, and 12 substances that do not conform to any of these groups.
Nine of the new substances reported in 2013 are used as active pharmaceutical 
ingredients in medicines. The monitoring of such substances under the Council Decision 
can provide essential early warning on the emerging misuse and abuse of medicines 
authorised within the EU and also in third countries (5). An example of this in 2013 was the 
report from Italy that tropicamide, which is used in medicine to dilate the pupils, was being 
injected by opioid users. A review of the available information suggests that the injection of 
tropicamide has been reported in some eastern European countries. It appears to be used 
to self-treat opioid withdrawal symptoms and for its euphorigenic and hallucinogenic 
effects.
A substantial part of the market in new psychoactive substances is those that are sold on 
the open market in head shops and online shops as ‘legal highs’ and ‘research chemicals’. 
In 2013 the EMCDDA’s monitoring of the Internet (6) identified 651 online shops selling 
these types of products to consumers in the EU (section 3.1.3). Europol has also gathered 
information from Member States on investigations regarding the online distribution of new 
substances in order to better understand how this market operates and the threats it 
poses.
Adding to the complexity of this online market is the sale of new substances as ‘food 
supplements’. This includes the plant kava kava and the medicine phenibut. These 
‘supplements’ are of particular concern because the retailers and products are typically 
not covered by existing drug monitoring systems, effectively creating a blind spot in our 
understanding of the market. Some of these products are widely available on popular 
e-commerce sites and online health-food shops, and in fitness equipment shops. In some 
cases these ‘supplements’ are marketed as ‘natural’, exploiting the general belief that they 
(4)  The term ‘synthetic cannabinoids’ is used here to include: synthetic cannabinoid receptor agonists (such as 




 receptor agonist); allosteric modulators (such as Org 27569) that change the 
structure of the cannabinoid receptors leading to altered activity when a ligand binds to the receptors; and 
substances that act as inhibitors of the fatty acid amide hydrolase (FAAH), which catalyses the intracellular 
hydrolysis of the endocannabinoid anandamide (such as URB597).
(5)  The terms ‘misuse’ and ‘abuse’ are used in their regulatory sense within the medicine regulatory system.  
See: www.ema.europa.eu/docs/en_GB/document_library/Other/2013/05/WC500143294.pdf 
(6) Monitoring was limited to retailers on the Surface Web selling direct to consumers. 
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are safe and healthy options for consumers. One product that that was sold as a sport 
supplement and analysed in 2013 was found to contain a derivative of methamphetamine 
(substance 17, Annex). This product has been sold in a number of countries including 
Sweden, the United Kingdom and the United States. 
In 2013 the sale of controlled drugs on the ‘hidden’ Deep Web, such as the now-defunct 
Silk Road, really came to the public’s attention. Less well known is that new psychoactive 
substances are also sold on the Deep Web, and work is required to better understand the 
importance to the EU drug market of such distribution networks, including sales to 
consumers.
It is of serious concern that illicit production within the EU was reported to Europol in 2013. 
Hungary, Poland and Slovakia have all reported the dismantling of illicit facilities where 
synthesis, processing and/or tableting of new psychoactive substances was taking place. 
These reports demonstrate that the processing of new substances within the EU is no 
longer limited to mixing and packaging, as organised crime groups have begun to invest 
resources in illicit production facilities.
The number and type of new psychoactive substances reported each year is critical to 
understanding the development and growth of the market. These numbers, however, fail to 
convey the enormous amount of work undertaken by the Early Warning System Network at 
the national and the EU level. For the EMCDDA and Europol, each report of a new 
substance requires that the information and analytical data is checked and assessed, that 
literature searches are run to find out what is known about the substance, and that a 
technical profile is created on the European Database on New Drugs (EDND) at the 
EMCDDA. Simultaneously, the information is recorded and analysed by the Focal Point 
Synergy at Europol, which is the hub for law enforcement data on synthetic drug crime, 
including new psychoactive substances. From there, the Early Warning System Network is 
formally notified about the substance, allowing laboratories, law enforcement, healthcare 
agencies, researchers, practitioners and policymakers to receive this critical data. This 
stage also marks the point at which the EMCDDA and Europol begin to monitor the new 
substance. Currently, more than 380 new substances are monitored. The EDND, which is 
updated on a daily basis, plays a critical role in this monitoring by providing round-the-
clock access for the Early Warning System Network to the latest information on new 
substances, including, chemistry, pharmacology, toxicity, law enforcement seizures and 
epidemiology.
In 2013 the EMCDDA and Europol also produced four Joint Reports on very different 
substances, in terms of their chemistry, pharmacology and the individuals who use them: 
AH-7921, an opioid with similar effects to morphine; 25I-NBOMe, a potent hallucinogen; 
MDPV, a stimulant that in animal studies appears to be more potent and longer lasting 
than cocaine; and methoxetamine, a dissociative sold as a ‘legal’ and ‘safer’ alternative to 
ketamine (section 4.2). Reflecting the growing diversity of the market, 2013 marked the 
first time that formal action on an opioid (AH-7921) has been required at the EU level. Also 
in 2013 the EMCDDA’s Scientific Committee conducted a risk assessment on the 
stimulant 5-IT after 24 deaths associated with its use were reported over a short time 
period (section 4.3).
While it is clear that many new substances will not gain a foothold as drugs in their own 
right and spread to broader groups of users, they are still capable of causing serious harm. 
The largely unknown pharmacology can pose serious risks to users. This is compounded by 
both the growing range of substances and the generally high availability. These problems 
are especially apparent when they are sold as ‘legal highs’ with no information provided to 
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the user of the actual substance(s) present, and as a result of an increasing number finding 
their way to the black market where they are sold as ecstasy, cocaine, ketamine, heroin or 
LSD to unsuspecting users. In addition, while much attention has been paid to the use of 
new substances by recreational users, these substances are also being used by problem 
drug users, including those who inject. This situation is presenting challenges for service 
providers, including low-threshold services such as needle and syringe programmes that 
often have limited experience of these drugs and their effects. Little is also known about 
the treatment requirements of users of new psychoactive substances, which in part may 
reflect the fact that many have emerged only recently.
Estimating the prevalence of use of new psychoactive substances continues to present 
challenges, especially through general population surveys. In some cases, such as with the 
synthetic cannabinoids, there is a clear discordance between the large number of multi-
kilogram seizures reported to the Early Warning System and the levels of use reported in 
surveys. During 2013 the EMCDDA continued to work with its partners on ways to 
strengthen epidemiological methods and indicators related to the use of new substances. 
This includes exploring the development of indicators based on waste water analysis.
Reports of serious adverse events from the Early Warning System Network — such as 
non-fatal intoxications that require hospital treatment, and deaths — provide signals of 
emerging harms. Reflecting the growing number of such reports, in 2013 the EMCDDA 
began to develop a framework to strengthen the toxicovigilance component of the Early 
Warning System. This system will facilitate the identification and reporting of serious 
events and will optimise the reported data in order to best analyse these signals. 
Ultimately this should allow the Member States and the EU to respond earlier to emerging 
harms. While there is still a long way to go to reach its full development, the EMCDDA has 
already begun to improve the quality of data that is reported by the Early Warning System 
Network related to serious adverse events. In addition, as a component of this system, the 
EMCDDA is developing a framework that allows it to more systematically monitor the 
media to pick up on these signals as early as possible and from a broader number of 
sources, including from countries outside Europe. In fact, the EMCDDA monitors the 
scientific and medical literature on a daily basis for reports of serious adverse events and 
data from nonclinical studies that help explain the cause of these events. These data are 
analysed and prioritised and are then fed into the broader monitoring process.
In 2013 the EMCDDA issued 16 public health alerts and advisories to the Early Warning 
System Network (section 4.4). Many of these concerned serious adverse events, 
particularly deaths, and/or hazards that had the potential to cause serious harm. Notably, 
alerts were issued on three potent new opioids — AH-7921, carfentanil, ocfentanil — that 
appear to have only been sold on the drug market for the past two years or so. The 
EMCDDA and Europol are highly concerned about the number and type of new synthetic 
opioids reported to the Early Warning System in the past two years. Five of these opioids 
are fentanyls, a family of drugs that have already caused hundreds of deaths in Europe and 
the United States since they first appeared as ‘designer drugs’ sold as ‘synthetic heroin’ or 
‘China white’ in California in the late 1970s. Adding to this concern is that some of the new 
opioids have already been sold as replacements for heroin. This includes a seizure made in 
Lithuania containing carfentanil (substance 6, Annex), which is usually used to tranquillise 
large animals such as elephants, and a seizure of ocfentanil in the Netherlands (substance 
62, Annex).
In September 2013 Europol initiated the collection of available information on the new 
substance 4,4′-DMAR, after eight deaths associated with the substance were reported by 
Hungarian police. 4,4′-DMAR is a derivative of the designer drug ‘U4Euh’ 
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(4-methylaminorex) and the weight-loss medicine aminorex, which was withdrawn after it 
caused an epidemic of pulmonary hypertension. As a result of the information provided by 
Hungary, Europol and the EMCDDA issued alerts to their respective partners within the 
Early Warning System Network (see ‘Update from 2014’, below).
The effective exchange of information on new psychoactive substances underpins an 
effective response. During 2013 the EMCDDA and Europol provided formal training in 
order to strengthen early warning at both the national and the EU level. Reflecting the 
globalised nature of this phenomenon, international cooperation with third countries was 
strengthened further. This included the bilateral exchange of technical information with 
law enforcement and healthcare agencies from the United States, Japan and Australia, 
among others. The importance of these global partnerships continues to be highlighted by 
the exchange of information on serious adverse events. In 2013 alerts were issued related 
to outbreaks of serious adverse events associated with synthetic cannabinoids that were 
reported to the EMCDDA by law enforcement agencies in the United States. In addition, 
during the Third International Forum on New Drugs experts from around the world came 
together to exchange experiences, identify information gaps and research needs and 
anticipate future developments and challenges.
I Update from 2014
There appears to have been no slowdown in the growth of the phenomenon in 2014. As of 
May, 37 new psychoactive substances had been reported to the Early Warning System.
The eight deaths associated with 4,4′-DMAR that were reported by Hungary in 2013 were 
joined by a further 18 deaths reported by the United Kingdom in February 2014, leading 
the EMCDDA and Europol to launch a Joint Report on 4,4′-DMAR in the same month. The 
substance continues to be intensively monitored by the Early Warning System. Twenty-
seven deaths associated with the substance have now been reported; a particular concern 
in this respect is that more than 260 kg of 4,4′-DMAR has been seized in the Netherlands, 
and in some countries it has been sold as ecstasy on the illicit drug market. The availability 
of 4,4′-DMAR may also mark an astonishing development in the ‘research chemical’ market 
after the suggestion that the distributors have conducted tests of the substance on 
animals, with the data from these tests being used as part of the marketing. If this is 
correct then distributors may be attempting to consolidate a ‘legal’ market in new 
substances.
Also in 2014 some 21 deaths and 13 non-fatal intoxications associated with the new 
opioid MT-45 have so far been reported. Of particular concern in this respect is that this 
substance appears to have only been sold on the drug market for the past six months or 
so. On the basis of these reports, a Joint Report on MT-45 was launched in April by the 
EMCDDA and Europol (substance 73, Annex). The substance continues to be intensively 
monitored by the Early Warning System.
The growing involvement of organised crime groups, apparently attracted by the large 
profits available in this market, is of serious concern to Europol. Analysis of intelligence 
reports provided by the Member States indicates that in the near future criminal groups 
based within the EU will expand their involvement in the trade, manufacture, trafficking 
and distribution of new psychoactive substances.
There is little doubt that enhanced monitoring systems within some national early warning 
systems are playing a key role in the early identification of serious adverse events and 
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other harms by the Early Warning System. Such systems will require adequate resources if 
they are to continue to supply this essential data and scale-up to provide enhanced 
coverage. Resources will also be required in order to replicate these enhancements in 
other settings and regions.
For the past few years the EDND has begun to feel the strain as a result of the huge 
increase in both the amount and the types of data now being reported. Resources are 
urgently required to ensure it can meet the needs of the EU both in the near future and in 
the longer term.
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I 3.  Implementation arrangements and cooperation with the European Union Pharmacovigilance system
I 3.1. Specific implementation arrangements
3.1.1. Assistance to national early warning systems
In 2013 the EMCDDA and Europol continued to provide support to the national early 
warning systems within the Reitox National Focal Points and Europol National Units in 
order to assist them in the identification of new substances. Assistance related to new 
psychoactive substances was also provided to Member States, institutions and agencies 
of the EU. 
The analytical data available to the Early Warning System Network continued to be 
expanded during 2013. In addition, data and information is now routinely provided on an 
informal basis by international partners, including Australia, the United States and Japan. 
This is an important aspect of the exchange of information and emphasises the global 
nature of the phenomenon. 
The EMCDDA also collects national risk assessments on new psychoactive substances, 
which are made available on the EDND in order to help identify emerging harms and to 
inform policy responses in the Member States. Similarly, legislative developments related 
to new substances reported by the Member States are also recorded and tracked.
Training was also provided to some of the Member States (section 3.1.4).
3.1.2. Annual meeting of the Early Warning System Network 
The 13th annual meeting of the Reitox Early Warning System Network took place on 27 
June 2013. The meeting was organised in conjunction with the second Europol law 
enforcement meeting on new psychoactive substances and the Third International 
Multidisciplinary Forum on New Drugs.
Over 70 representatives from the Early Warning System Network and Europol networks in 
the 28 Member States, Turkey and Norway attended the forum together with delegates 
from 10 third countries. Experts also attended from a wide range of disciplines. This 
included individuals from academic and operational backgrounds, such as epidemiology, 
forensic science, healthcare, law enforcement, criminology and policy. The forum aimed to 
identify information gaps and research needs, anticipate future developments and 
challenges and explore the role that can be played by law enforcement. The topics 
discussed included:
n  historical context, public health perspective, the motivations of users, the role of law 
enforcement, challenges for drug policy;
n  national, regional and global perspectives on new drugs, including presentations on 
significant developments and initiatives taking place around the globe;
n  how emerging harms can be detected, monitored and understood by the work of 
forensic science, toxicology and healthcare disciplines;
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n  the role of law enforcement in the response to new drugs, including the difficulties 
faced by the growing interplay between new drugs and illicit drug markets;
n  good practice and novel approaches, including what can be learned from the users of 
new drugs; and,
n  the response to new drugs, which included a discussion of the recent policy 
developments in New Zealand.
3.1.3. Monitoring the online availability of new psychoactive substances 
In 2013 the EMCDDA, in partnership with some of the national focal points, undertook an 
Internet monitoring exercise in 18 languages of the EU, Norwegian and Russian. The aim of 
the exercise was to provide a snapshot of the online sale of new psychoactive substances 
to consumers within the EU. The snapshot identified 651 shops that typically sold new 
substances as ‘legal high’ products or ‘research chemicals’; in some cases products were 
also identified that were sold as ‘food supplements’. In comparison, the previous snapshot 
exercise in January 2012 identified 693 shops, while the snapshots conducted in January 
2011 and 2010 identified 314 and 170 shops, respectively (7,8).
A targeted Internet snapshot in English was also conducted in 2013 to provide data to 
support the risk assessment of 5-IT (section 4.3.1).
3.1.4. Supporting activities
During 2013 the EMCDDA and Europol continued to be prominently involved in organising 
events and participating in activities that are designed to develop the Early Warning 
System Network and provide support to others working in the field of new psychoactive 
substances. These events and activities provide a platform to improve collaboration 
among partners and promote best practice in order to strengthen early warning activities. 
Significant activities carried out in 2013 are reported below.
In April a Reitox Academy training event examining contemporary approaches to drug 
monitoring was organised in Prague, the Czech Republic for Western Balkan countries and 
Turkey. The EMCDDA provided a keynote lecture on new psychoactive substances, 
including the critical role that the Internet plays in this phenomenon. The event also 
incorporated a training session on monitoring the supply of new psychoactive substances 
on the Internet. A pilot Internet snapshot in Balkan languages (Montenegrin, Macedonian, 
Bosnian, Serbian, Albanian, Croatian and Turkish) was implemented during the training 
session.
In May training was provided at the Workshop on New Psychoactive Substances, the 
Health Dimension in Zagreb, Croatia, funded under the European Commission’s TAIEX 
instrument and organised by the Croatian Office for Combatting Drug Abuse. Also in May 
the annual meeting of the Drugs Working Group of the European Network of Forensic 
Science Institutes (ENFSI) was held in Dubrovnik, Croatia, in which the EMCDDA actively 
participated as an associate member of the network.
(7)  EMCDDA (2011), Online sales of new psychoactive substances/‘legal highs’: summary of results from the 2011 
multilingual snapshots, EMCDDA, Lisbon (www.emcdda.europa.eu/publications/scientific-studies/2011/
snapshot).
(8)  It is important to note that the data included in different snapshots may not be directly comparable, due to changes 
in the methodology that have increased the quality and coverage of these surveys over time; in addition, changes 
in technology, such as the algorithms used by search engine, can also affect the comparability between different 
snapshots. 
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In June the EMCDDA assisted Europol by providing training input at the Cepol–Europol 
International Illicit Synthetic Drug Laboratory Dismantling Course, held at the national 
police-training centre in Legionowo, Poland.
In September the Second International Conference on Novel Psychoactive Substances 
took place in Swansea, the United Kingdom. As well as co-organising the event, the 
EMCDDA participated with two keynote speeches and chaired or co-chaired the plenary 
and parallel sessions of the conference.
In October a meeting of forensic drug experts representing different institutions took place 
at the EMCDDA in Lisbon, Portugal. During this meeting the participants explored the 
possibilities for improving processes, particularly in relation to the interaction of the 
forensic community with the Early Warning System.
In November the EMCDDA attended the Spanish National Early Warning System meeting 
in Madrid to provide a European overview and best practice example to strengthen the 
national network. 
The EMCDDA also organised or participated in a number of meetings with dedicated 
sessions on new psychoactive substances, reflecting the relevance of this area for 
traditional illicit drug areas, and established key epidemiological indicators. This included 
meetings covering general population surveys, drug-related deaths and problem drug use. 
In May the EMCDDA organised the first international multidisciplinary conference on 
detecting illicit drugs in wastewater, Testing the Waters, with a dedicated session on the 
potential of sewage analysis for identifying and monitoring population-level trends of new 
drugs in wastewater. In October the EMCDDA co-organised with COPOLAD (9) a thematic 
twinning training on analysis, interpretation and dissemination of drug-related data to 
facilitate decision-making.
I 3.2. Cooperation with the EMA and the Pharmacovigilance system
During 2013 the EMA and EMCDDA continued to regularly exchange information on new 
psychoactive substances according to their respective obligations under the Council 
Decision and EU pharmacovigilance legislation and the working arrangement between the 
two agencies (10). This included ad hoc reports relating to the misuse and abuse of 
medicinal products, or the active pharmaceutical ingredients used therein, that had been 
notified as new psychoactive substances, in order to support the Pharmacovigilance 
system. At the request of the EMCDDA, the EMA provided pharmacovigilance data on 
phenibut (notified in 2010) and information on authorised medicinal products containing 
tropicamide (substance 25, Annex), and pharmacovigilance data on these products related 
to their misuse, including by injection. Formal consultations and exchange of information 
took place in order to prepare the Joint Reports on 25I-NBOMe, AH-7921, MDPV and 
methoxetamine (section 4.2). In addition, at the request of the EMA, the EMCDDA 
undertook a data collection exercise with the Early Warning System Network to provide 
information on the misuse and abuse of pregabalin (notified in 2009).
(9)  Cooperation programme between the European Union and Latin America, aiming to improving the coherence, 
balance and impact of drugs policies, trough the exchange of mutual experiences, bi-regional coordination and the 
promotion multisectoral, comprehensive and coordinated responses.
(10)  www.emcdda.europa.eu/attachements.cfm/att_185319_EN_EMA-EMCDDA-2012workingarrangement.pdf 
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I 4. Activities
I 4.1. New psychoactive substances notified in 2013
Eighty-one new psychoactive substances were notified for the first time in 2013 (Table 1 
and Annex). This continues the year on year increase in the number of new substances that 
have been notified since 2008 (Figure 1). 
Technical profiles were created on the EDND for each of the notified substances and five 
substances of interest. During the course of 2013 a total of 444 reporting forms were 
submitted by the Early Warning System Network, which were processed, analysed and 
added to the EDND; while 300 technical profiles on the EDND were updated with the 
information from these forms and from other sources, including regular searches of the 
scientific and medical literature that are conducted by the EMCDDA and additional law 
enforcement information provided by Europol.
Technical assistance, advice and feedback were provided to the Member States on a daily 
basis. Sixteen public health alerts or advisories were issued to the Early Warning System 
Network (section 4.4). Additional data collection and analysis took place on an ad hoc 
basis, including for the Joint Reports on 25I-NBOMe, AH-7921, MDPV and methoxetamine 
(section 4.2). 
As part of a process that began in 2012, the EMCDDA has been reviewing its classification 
system for new psychoactive substances. In the main it is possible to group some 
substances by their chemical family, or in the case of the synthetic cannabinoids by their 
mode of action. The former has long been the case with the phenethylamines, tryptamines, 
piperazines and cathinones. To take account of the increasing diversity of substances that 
have been notified in recent years, six new categories have been introduced during 2013: 
arylcyclohexylamines, aminoindanes, arylalkylamines, benzodiazepines, piperidines and 
pyrrolidines. The category of ‘opioids’ has also been introduced based on mode of action; 
this group contains eleven substances, ten of which have been notified since 2012. A 
category has also been created for plants and extracts of plants; no substances were 
reported in this group in 2013. Substances that do not conform to the groups described 
above were grouped separately, in an ‘others’ category.
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TABLE 1













Piperidines and pyrrolidines 1
Plants and extracts 0
FIGURE 1
The number of new psychoactive substances notified for the first time to the Early 
Warning System since May 2005, by year (11)
 Synthetic cannabinoids   Phenethylamines   Other substances   Arylalkylamines   Cathinones  
 Opioids   Benzodiazepines   Piperidines and pyrrolidines   Piperazines   Arylcyclohexylamines  
 Aminoindanes   Tryptamines   Plants and extracts








(11)  As noted, the 2012 Annual Report listed 73 substances as notified through the Early Warning System in 2012; this 
figure should have been 74. The synthetic cannabinoid JWH-302 (1-pentyl-3-(3-methoxyphenylacetyl)indole) was 
identified by Germany in August 2012 but was not included in the 2012 Annual Report. 
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I 4.2. EMCDDA–Europol Joint Reports
In accordance with Article 5 of the Council Decision, after a review of the available 
information on the new psychoactive substances 25I-NBOMe, AH-7921, MDPV and 
methoxetamine, a formal procedure for the collection of information on these four new 
substances was launched by the EMCDDA and Europol on 7 October 2013. The Joint 
Reports were submitted to the Council, the Commission and the EMA on 16 December 
2013. A summary of the key findings for each of the four Joint Reports is provided below.
On the basis of the information provided therein, on 29 January 2014 the Council 
requested that formal risk assessments be conducted on the substances. In accordance 
with Article 6 of the Council Decision, the risk assessments were conducted by the 
extended Scientific Committee of the EMCDDA on 1 and 2 April 2014. A Risk Assessment 
Report for each substance was submitted to the Council and the Commission on the 22 
April 2014 (12).
4.2.1. Joint Report on 25I-NBOMe
25I-NBOMe is a substituted phenethylamine. It is a potent full agonist of the serotonin 
5-HT
2A
 receptor and appears to have hallucinogenic effects. It has been available on the EU 
drug market since at least May 2012 and has been detected in 23 Member States and 
Norway. Severe toxicity associated with its use has been reported in four Member States 
and one death associated with 25I-NBOMe has been analytically confirmed. Seven 
countries have reported that it has been sold as LSD or as a ‘legal’ alternative to LSD. On 
this basis the potential impact from the further spread of 25I-NBOMe (and related 
‘NBOMe’ compounds) on public health is a key concern (13).
4.2.2. Joint Report on AH-7921
AH-7921 is a synthetic opioid. It has been available in the EU since at least July 2012 and 
has been detected in seven Member States and Norway. In most cases it has been seized 
in small quantities as a powder. Over a short period of time it has been associated with 15 
deaths and six non-fatal intoxications in three countries. The similarity of AH-7921 to 
morphine in terms of pharmacology is a key concern. This may play an important role in the 
further spread of AH-7921 by opioid users, including the injecting population (14).
4.2.3. Joint Report on MDPV
MDPV is a synthetic cathinone derivative, which is closely related to pyrovalerone. MDPV 
has been present in the EU drug market since at least November 2008 and has been 
detected in 99 deaths and up to 107 non-fatal intoxications, particularly in Finland and the 
United Kingdom. There are some indications that it has been sold as a ‘legal’ or synthetic 
version of cocaine and it has also been found in tablets resembling ‘ecstasy’. Large 
seizures have been made at borders and police operations have targeted its supply. 
(12)  The Risk Assessment Reports are available at www.emcdda.europa.eu/publications/risk-assessments.
(13)  EMCDDA and Europol (2014), EMCDDA–Europol Joint Report on a new psychoactive substance: 25I-NBOMe 
(4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine), EMCDDA, Lisbon, January 2014 (www.emcdda.
europa.eu/publications/joint-report/25I-NBOMe).
(14)  EMCDDA and Europol (2014), EMCDDA–Europol Joint Report on a new psychoactive substance: AH-7921 
(3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide), EMCDDA, Lisbon, January 2014  
(www.emcdda.europa.eu/publications/joint-report/AH-7921).
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Powder seizures have been reported, including multi-kilogram quantities. Most Member 
States have control measures at the national level that cover MDPV; however, it continues 
to be available and this is concerning (15).
4.2.4. Joint Report on methoxetamine
Methoxetamine is an arylcyclohexylamine, closely related in many respects to ketamine. It 
has been available on the EU drug market since at least September 2010 and has been 
detected in 22 Member States, Turkey and Norway. Multi-kilogram quantities of the 
substance in powder form have been seized. Twenty deaths and 110 non-fatal 
intoxications associated with the substance have been reported. As methoxetamine is 
marketed as a legal and ‘bladder-friendly’ alternative to ketamine and is being sold directly 
on the illicit drug market at the same time as ketamine, a key concern is that these factors 
may play a role in the further spread of the substance (16).
I 4.3. Risk assessments
4.3.1. Risk assessment of 5-IT
During 2012 a Joint Report on 5-IT (5-(2-aminopropyl)indole) was prepared by the 
EMCDDA and Europol. It was submitted to the Council, Commission and EMA on 12 
December 2012 (17). This led to a request from the Council for a formal risk assessment in 
January 2013. The risk assessment was conducted, in accordance with Article 6 of the 
Council Decision, by the extended Scientific Committee of the EMCDDA on 16 April 2013, 
which included a representative from Europol, the EMA and the Commission. Discussions 
during the risk assessment focused on the 24 deaths and 20 non-fatal intoxications 
associated with 5-IT that had been reported. The deaths occurred in four Member States 
over a period of five months in 2012, raising concern that if 5-IT were to become more 
widely available and used, the implications for public health could be significant. Full 
details are provided in the EMCDDA report on the risk assessment (18).
On 7 October 2013 the Council adopted a decision to subject 5-IT to control measures 
across the EU (19). 
I 4.4. Public health alerts and advisories
One of the activities of the Early Warning System that provides added value to the Member 
States is public health alerts and advisories. Usually these concern deaths or other serious 
adverse events associated with new psychoactive substances; they can also include 
(15)  EMCDDA and Europol (2014), EMCDDA–Europol Joint Report on a new psychoactive substance: MDPV 
(3,4-methylenedioxypyrovalerone), EMCDDA, Lisbon, January 2014 (www.emcdda.europa.eu/publications/
joint-report/MDPV).
(16)  EMCDDA and Europol (2014), EMCDDA–Europol Joint Report on a new psychoactive substance: methoxetamine 
(2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone), EMCDDA, Lisbon, January 2014 (www.emcdda.europa.eu/
publications/joint-report/methoxetamine).
(17)  EMCDDA and Europol (2012), EMCDDA–Europol Joint Report on a new psychoactive substance, 
5-(2-aminopropyl)indole, EMCDDA, Lisbon (www.emcdda.europa.eu/publications/joint-reports/5-IT).
(18)  EMCDDA (2014), Report on the risk assessment of 5-(2-aminopropyl)indole in the framework of the Council 
Decision on new psychoactive substances, Publications Office of the European Union, Luxembourg  
(www.emcdda.europa.eu/publications/risk-assessment/5-IT).
(19)  Council Decision of 7 October 2013 on subjecting 5-(2-aminopropyl)indole to control measures (2013/496/EU), 
OJ L 272, 12.10.2013, pp. 44–45.
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hazards that have the potential to cause serious harm (20). In addition, information is 
exchanged on emerging trends in new uses of psychoactive substances that are controlled 
under the United Nations drug conventions and that may pose a potential risk to public 
health. Alerts and advisories may also provide information on possible public health 
related measures in accordance with the mandate and procedures of the EMCDDA.
Sixteen public health alerts and advisories were issued to the Early Warning System 
Network during 2013. A selection is provided below (21). 
Carfentanil
An alert was issued in February 2013 after the Latvian National Focal Point reported that 
the highly potent opioid and fentanyl derivative had been identified in a seizure of powder 
by Latvian Police. The information also noted that this substance had been associated with 
a number of unconfirmed deaths in the country.
AH-7921
An alert was issued in February 2013 after the Norwegian National Focal Point reported 
that the opioid AH-7921 had been identified in a seizure of powder and in the contents of a 
used syringe that was seized in connection with a death that was believed to be linked to 
the substance. Other alerts were issued during 2013 related to AH-7921 after reports of 
deaths associated with the substance were received from Sweden and Norway.
25I-NBOMe
An alert was issued in February 2013 after the United Kingdom National Focal Point 
reported seven serious non-fatal intoxications associated with the use of the potent 
hallucinogen 25I-NBOMe that occurred in January 2013.
4,4′-Dimethylaminorex (4,4′-DMAR)
An alert was issued in October 2013 after the Hungarian National Focal Point reported 
eight deaths associated with 4,4′-DMAR, which is believed to be a stimulant-type 
substance. This alert facilitated work by the United Kingdom National Early Warning 
System in identifying 18 deaths associated with 4,4′-DMAR, which were subsequently 
reported to the Early Warning System in February 2014.
Ocfentanil
An alert was issued in September 2013 after the Netherlands National Focal Point 
reported the identification of the opioid and fentanyl derivative ocfentanil in a seizure by 
Dutch police, which may have been intended for sale on the drug market as ‘synthetic 
heroin’.
ADB-PINACA and 5F-ADBICA
An advisory was issued in September 2013 after information provided by law enforcement 
agencies in the United States, supplemented by information from the EMCDDA’s 
(20)  Alerts and advisories issued by the Early Warning System are not legally binding and Member States are not 
obliged to act upon them.
(21)  Note that the detection of new psychoactive substances in post-mortem biological samples does not necessarily 
imply a causal role in the death.
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monitoring of open source information, identified a series of non-fatal intoxications in the 
United States associated with ADB-PINACA and 5F-ADBICA. These substances are known 
to be present on the EU drug market and have been reported by several Member States.
5-EAPB
An alert was issued in December 2013 after the Swedish National Focal Point reported a 
death associated with 5-EAPB, a substance that has a chemical structure very similar to 
the well-known ecstasy drug MDMA.
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I 5. Conclusions
The year 2013 saw the sustained growth of the market in new psychoactive substances 
within the EU. The new psychoactive substances reported in that year unequivocally 
demonstrate a growing diversity in the types of substances being sold as ‘legal’ 
alternatives to controlled drugs. Of particular concern from a public health perspective are 
the new synthetic opioids that have been identified on the drug market in the past two 
years, such as AH-7921, MT-45, carfentanil and ocfentanil. These developments are 
compounded by the increasing involvement of organised crime groups, which appear to be 
drawn to the market by the potentially large profits. Europol’s analysis of intelligence 
reports indicates that in the near future criminal groups based within the EU may expand 
their involvement in the trade, manufacture, trafficking and distribution of new 
psychoactive substances.
Despite these challenges, the Early Warning System and the EMCDDA–Europol Joint 
Reports and the risk assessment conducted by the EMCDDA extended Scientific 
Committee continue to demonstrate the added value and strength of the EU system by 
ensuring robust data-driven analysis, assessment and response to the harms posed by 
new psychoactive substances.
The EMCDDA and Europol have devoted substantial internal resources to ensure that the 
current information exchange system set up under Council Decision 2005/387/JHA, and 
operationalised as the Early Warning System, has been successfully implemented on a 
continuous basis. Through the support of its partners, including the EMA, the Early 
Warning System provides added value to the Member States by playing an essential role 
as a sentinel network that ensures that they have access to the most up-to-date 
information on new psychoactive substances both from across Europe and beyond. The 
Early Warning System Network continues to grow, as does the amount and quality of the 
information that it collects. This continued development is underpinned by the Reitox 
National Focal Points and the Europol National Units, which need to be adequately 
supported. There is little doubt that enhanced national monitoring systems are playing a 
key role in the early identification of harms by the Early Warning System. Such systems will 
require adequate resources if they are to continue to supply this essential data and 
scale-up to provide enhanced coverage. Resources will also be required in order to 
replicate these enhancements in other settings and regions. In addition, there is a critical 
need for a strengthened data collection mechanism so that the Early Warning System can 
both effectively cope with the recent significant growth in the data and ensure that it can 
be monitored.
Monitoring new psychoactive substances is event-based. It is driven by the identification of 
new psychoactive substances in laboratory settings that are predominantly not research 
focused. These analytical and toxicological laboratories are the cornerstones of the Early 
Warning System. They are located at law enforcement, private sector, (public) health, 
academic establishments, etc. This is routine work for these laboratories and they urgently 
require both the enhanced provision of analytical data through a strengthened European 
Database on New Drugs (EDND) (see below) and a cost-effective mechanism to share 
reference standards easily and rapidly within the EU.
Given the growing role that organised crime groups are likely to play in the manufacture 
and supply of new psychoactive substances in the future, it is essential that adequate 
resources and expertise are available to law enforcement agencies at both the national 
and the EU level.
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The toxicovigilance component of the Early Warning System is the mechanism that allows 
the early detection of an emerging toxicological problem — and an initial assessment of 
the potential scale of the problem — related to a new substance at both the national and 
the EU level. This allows public health warnings to be issued to the Early Warning System 
Network, and the substance to be placed under intensive monitoring. In some cases this 
may also lead to formal action through a Joint Report, and, where necessary a risk 
assessment. In order for the EMCDDA to meet the increased needs and demands arising 
from the phenomenon, at both the national and the EU level, the identification, reporting 
and monitoring of serious adverse events requires strengthening.
For many years the European Database on New Drugs (EDND) has served the EU well by 
acting as a reference point for the available information on new psychoactive substances. 
However, adequate resources are not available to enable its development to keep pace 
with the amount and type of data arising from the increasing number of substances that 
are being identified and to ensure effective monitoring. The EDND should be strengthened. 
A core part of this work will require the development of a new infrastructure that will allow 
the secure electronic submission of data through standard web-based structured forms 
and facilitate the central analysis of data and production of reports. In addition to being 
able to provide real time information on a new drug (or a particular aspect of a new drug 
such as its detection in a particular ‘legal high’ product or reports of serious adverse 
events), the system should be able to provide an overview of the phenomenon as a whole 
to stakeholders. Resources are urgently required in order to ensure it can meet the needs 
of the EU both in the near future and in the longer term.
By its very nature, the risk assessment process is completed in a short time frame. As a 
result, limited data is available, and the process is principally focused on the data related 
to acute harm. It is important to recognise here that the data provided and collected 
through the Early Warning System will be essential to this process, particularly in relation 
to serious adverse events. In addition, targeted non-clinical studies that characterise the 
pharmacological and toxicological properties of the new psychoactive substances will be 
required for the risk assessment process in order to understand the data reported through 
the Early Warning System. Sufficient resources must be made available so that these data 
can be provided.
It is hoped that the information and analysis provided by the EMCDDA and Europol in this 
report will provide a greater insight into the growing complexity of the market in new 
psychoactive substances and the subsequent challenges that the Member States and the 
EU are likely to face in the near future. It is also hoped that the report will inform the policy 
responses currently being discussed at the EU level.
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I  AnnexNew psychoactive substances first notified to the Early Warning System in 2013 under the terms of Council Decision 2005/387/JHA
1.  5-MAPB (1-(benzofuran-5-yl)-N-methylpropan-2-amine) — 3 January 2013, United 
Kingdom.
2.  4-Fluorocathinone (2-amino-1-(4-fluorophenyl)propan-1-one) — 10 January 2013, 
Finland.
3.  JWH-methylcyclohexane-8quinolinol (Quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-
carboxylate) — 29 January 2013, Spain.
4.  A-834,735 ([1-(tetrahydropyran-4-ylmethyl)indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)
methanone) — 29 January 2013, Poland.
5.  JWH-368 ([5-(3-fluorophenyl)-1-pentyl-pyrrol-3-yl]-(1-naphthyl)methanone) — 
7 February 2013, Latvia.
6.  Carfentanil (methyl 1-(2-phenylethyl)-4-[phenyl(propionyl)amino]-4-
piperidinecarboxylate) — 12 February 2013, Latvia.
7.  EAM-2201 ((4-ethyl-1-naphthyl)-[1-(5-fluoropentyl)indol-3-yl]methanone) — 
15 February 2013, Sweden.
8.  Flubromazepam (7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one) 
— 7 March 2013, Germany.
9.  5F-PB22 (8-quinolyl 1-(5-fluoropentyl)indole-3-carboxylate) — 15 March 2013, 
Belgium.
10.  JWH-307 brominated derivative ((5-(2-bromophenyl)-1-pentyl-1H-pyrrol-3-yl)
(naphthalen-1-yl)methanone) — 4 April 2013, Germany.
11.  JWH-030 (naphthalen-1-yl(1-pentyl-1H-pyrrol-3-yl)methanone) — 4 April 2013, 
Germany.
12.  JWH-145 (naphthalen-1-yl(1-pentyl-5-phenyl-1H-pyrrol-3-yl)methanone) — 4 April 
2013, Germany.
13.  UR-144 heptyl derivative ((1-heptyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)-
methanone) — 17 April 2013, Sweden.
14.  3,4-dichloromethylphenidate (methyl (2R)-2-(3,4-dichlorophenyl)-2-[(2R)-piperidin-2-
yl]acetate) — 17 April 2013, Sweden.
15.  25H-NBOMe (2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine) — 24 April 
2013, Sweden.
16.  URB-597 ([3-(3-carbamoylphenyl)phenyl] N-cyclohexylcarbamate) — 24 April 2013, 
Poland.
17.  N-ethyl-1-phenylbutan-2-amine — 2 May 2013, Sweden.
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18.  AB-PINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-
carboxamide) — 21 May 2013, Sweden.
19.  α-PVT (2-(pyrrolidin-1-yl)-1-(thiophen-2-yl)pentan-1-one) — 21 May 2013, Hungary.
20.  A-836,339 (N-[3-(2-methoxyethyl)-4,5-dimethyl-1,3-thiazol-2-ylidene]-2,2,3,3-
tetramethylcyclopropane-carboxamide) — 3 June 2013, Hungary.
21.  4-methylbuphedrone, N-benzyl derivative (2-(benzylamino)-1-(4-methylphenyl)
butan-1-one) — 5 June 2013, Finland.
22.  2-Me-DMT (N,N-dimethyl-2-(2-methyl-1H-indol-3-yl)ethanamine) — 5 June 2013, 
Finland.
23.  4-MeO-α-PVP (1-(4-methoxyphenyl)-2-(pyrrolidin-1-yl)pentan-1-one) — 12 June 
2013, Finland.
24.  NMP (1-methylpyrrolidin-2-one) — 13 June 2013, Italy.
25.  Tropicamide (N-ethyl-3-hydroxy-2-phenyl-N-(pyridin-4-ylmethyl)propanamide) —  
2 July 2013, Italy.
26.  RH-34 (3-[2-(2-methoxybenzylamino)ethyl]-1H-quinazoline-2,4-dione) — 4 July 2013, 
France.
27.  2-(2,3-dimethoxyphenyl)-N-(3,4,5-trimethoxybenzyl)ethanamine — 4 July 2013, 
France.
28.  JTE-907 (N-(benzo[1,3]dioxol-5-ylmethyl)-7-methoxy-2-oxo-8-pentyloxy-1,2-
dihydroquinolin-3-carboxamide) — 4 July 2013, Germany.
29.  AB-FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-
3-carboxamide) — 4 July 2013, Belgium.
30.  5F-AB-PINACA (N-(1-carbamoyl-2-methyl-propyl)-1-(5-fluoropentyl)indazole-3-
carboxamide) — 5 July 2013, Belgium.
31.  Mebroqualone (3-(2-bromophenyl)-2-methylquinazolin-4(3H)-one) — 5 July 2013, 
United Kingdom.
32.  Allylescaline (4-allyloxy-3,5-dimethoxy-phenethylamine) — 8 July 2013, Denmark.
33.  α-PEP (1-phenyl-2-(1-pyrrolidinyl)heptan-1-one) — 8 July 2013, Sweden.
34.  5-EAPB (1-(1-benzofuran-5-yl)-N-ethylpropan-2-amine) — 11 July 2013, United 
Kingdom.
35.  Mephtetramine (2-((methylamino)methyl)-3,4-dihydronaphthalen-1(2H)-one) — 
11 July 2013, United Kingdom.
36.  Escaline (3,5-dimethoxy-4-ethoxyphenethylamine) — 15 July 2013, Germany.
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37.  βk-PBDB (1-(1,3-benzodioxol-5-yl)-2-(propylamino)butan-1-one) — 17 July 2013, 
Czech Republic.
38.  Proscaline (2-(3,5-dimethoxy-4-propoxyphenyl)ethanamine) — 7 August 2013, 
Netherlands.
39.  W-15 ((E)-4-chloro-N-(1-phenethylpiperidin-2-ylidene)benzenesulfonamide) — 
12 August 2013, Spain.
40.  Nitracaine (3-(N,N-diethylamino)-2,2-dimethylpropyl-4-nitrobenzoate) — 13 August 
2013, Sweden.
41.  Diclazepam (7-chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-
2-one) — 26 August 2013, Germany.
42.  Methoxetamine brominated derivative (2-(2-bromo-5-methoxy-phenyl)-2-(ethylamino)
cyclohexanone) — 28 August 2013, Poland.
43.  25iP-NBOMe (2-[2,5-dimethoxy-4-(propan-2-yl)phenyl]-N-(2-methoxybenzyl)
ethanamine) — 6 September 2013, Finland.
44.  3C-P (1-(3,5-dimethoxy-4-propoxyphenyl)propan-2-amine) — 6 September 2013, 
Finland.
45.  3C-E (1-(4-ethoxy-3,5-dimethoxyphenyl)propan-2-amine) — 6 September 2013, 
Finland.
46.  25I-NBMD (N-(1,3-benzodioxol-4-ylmethyl)-2-(4-iodo-2,5-dimethoxy-phenyl)
ethanamine) — 6 September 2013, Poland.
47.  6-MAPB (1-(benzofuran-6-yl)-N-methylpropan-2-amine) — 10 September 2013, 
United Kingdom.
48.  LY2183240 (N,N-dimethyl-5-[(4-biphenyl)methyl]tetrazole-1-carboxamide) — 
10 September 2013, United Kingdom.
49.  Methoxypiperamide ((4-methoxyphenyl)(4-methylpiperazine-1-yl)methanone) 
— 11 September 2013, United Kingdom. 
50.  bk-MPA (2-(methylamino)-1-(thiophenyl-2-yl)propan-1-one) — 12 September 2013, 
Hungary.
51.  AM-1248 azepane isomer ((adamant-1-yl)[1-(1-methylazepan-3-yl)-1H-indol-3-yl]
methanone) — 26 September 2013, Hungary.
52.  Methallylescaline (2-[3,5-dimethoxy-4-[(2-methyl-prop-2-en-1-yl)oxy]phenyl]
ethanamine) — 11 October 2013, Sweden.
53.  C30-NBOMe (2-(4-chloro-2,5-dimethoxy-phenyl)-N-[(3,4,5-trimethoxyphenyl)methyl]
ethanamine) — 11 October 2013, Sweden.
54.  ADBICA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-
carboxamide), 11 October 2013, Sweden.
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55.  Gabapentin (2-[1-(aminomethyl)cyclohexyl]acetic acid) — 15 October 2013, Belgium.
56.  Sibutramine (1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethyl-1-butanamine) — 
15 October 2013, United Kingdom.
57.  Venlafaxine (1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol) — 
15 October 2013, Austria.





ethanamine) — 23 October 2013, Hungary.
60.  Diphenhydramine (2-(diphenylmethoxy)-N,N-dimethylethanamine) — 23 October 
2013, United Kingdom.
61.  Atomoxetine ((3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine) — 
24 October 2013, Denmark.
62.  Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)-4-piperidinyl]
acetamide) — 24 October 2013, Netherlands.
63.  6-EAPB (1-(benzofuran-6-yl)-N-ethylpropan-2-amine) — 28 October 2013, 
Netherlands.
64.  AM-6527 5-fluoropentyl derivative (1-(5-fluoropentyl)-N-(napthalen-2-yl)-1H-indole-
3-carboxamide) — 7 November 2013, Germany.
65.  4-MMA (N-methyl-1-(4-methylphenyl)propan-2-amine) — 13 November 2013, Poland.
66.  AM-2201 indazole analogue ([1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)
methanone) — 15 November 2013, Sweden.
67.  N-methyl-2-aminoindane (N-methylindan-2-amine) — 20 November 2013, Denmark.
68.  Embutramide (N-[2-ethyl-2-(3-methoxyphenyl)butyl]-4-hydroxy-butanamide) — 
26 November 2013, Bulgaria.
69.  ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-
indazole-3-carboxamide) — 28 November 2013, Turkey and Germany.
70.  ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-
carboxamide) — 3 December 2013, United Kingdom.
71.  βk-2C-B (2-amino-1-(4-bromo-2,5-dimethoxyphenyl)ethan-1-one) — 3 December 
2013, United Kingdom.
72.  Butorphanol (17-cyclobutylmethyl-morphinan-3,14-diol) — 3 December 2013, 
Denmark.
73.  MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine) — 5 December 2013, Sweden.
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74.  Lysergic acid 2,4-dimethylazetidide (‘LSZ’) ([(2S,4S)-2,4-dimethylazetidin-1-yl]-[(9R)-
7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-yl]methanone) — 10 
December 2013, Slovenia.
75.  N,N-diethyl-2-(1-pentyl-1H-indol-3-yl)-4-thiazole-methanamine — 18 December 
2013, Germany.
76.  N-(2-methoxyethyl)-N-(1-methylethyl)-2-(1-pentyl-1H-indol-3-yl)-4-thiazole-
methanamine — 18 December 2013, Germany.
77.  1-(Cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-1H-benzimidazole-5-
carboxamide — 18 December 2013, Germany.
78.  A-796,260 isomer, ((E)-3,4,4-trimethyl-1-[1-(2-morpholinoethyl)indol-3-yl]pent-2-en-1-
one) — 18 December 2013, Germany.
79.  SDB-006 (N-benzyl-1-pentyl-1H-indole-3-carboxamide) — 19 December 2013, 
Finland.
80.  5F-SDB-006 (N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide) — 19 December 
2013, Finland.
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